GBA Group Pharma (ABF) Completes Expansion and Scale-Up Project in Anticipation of Brexit

- Vienna facilities more than doubled in size to increase capacities for clinical trial import and release activities

- Expansion makes the company one of the few in Europe capable of meeting Brexit-related demand for clients doing business in the EU

GBA Group Pharma announced that its subsidiary ABF Pharmaceutical Services, has completed the expansion of its Vienna GMP facilities for Investigational Medicinal Products (IMP) and Investigational New Drug (IND) clinical supply chains and commercial product supply including QP services.

Before the expansion, ABF was the largest international full-service provider for the import, export and CTSM (clinical trial supply management) in Austria. Now the company is one of the largest in Europe; ready to meet the growing needs of its international pharmaceutical and biotechnology clients.

ABF is a fully owned subsidiary of the GBA Group (Hamburg, Germany) and part of the GBA Group Pharma Division, which ranks among the largest and most experienced service groups in the European pharmaceutical and biotech sector.

“We are the one-stop solution for pharma and biotech companies looking to do business in Europe, which need support with CTSM, QP services, central laboratory, analytical services and preclinical services. The expansion of our GMP site for CTSM and commercials enables us to meet clients` increasing demands related to the UK leaving the EU and implementation of any European Medicines Agency (EMA) regulations and restrictions,” said Elisabeth Lackner, CEO of GBA Group Pharma & ABF. “We are now able to solve any Brexit related issues with clinical trials or supply of approved drugs throughout Continental Europe,” she added.

The Vienna facilities’ doubling in size and increased capacity, is designed with an eye for the future and anticipated growth in the global healthcare sector. The expansion includes over 250 clinical studies per day. In addition, the company can now offer 1,089 pallet spaces (948 at room temperature / 141 with cold storage), five packaging suites (primary & secondary pack- aging / cold chain) and a GMP warehouse for IMPs and commercial drugs.

To achieve best results for clients GBA Group Pharma offers services in CTSM and commercials (ABF), central laboratory (LKF Laboratory for Clinical Trials, Germany / Kiel), in the preclinical area (Pharmacelsus, Germany / Saarbrücken) and analytical testing (GBA Pharma Labs, Germany / Martinsried, Gräfelfing and Ulm).

JP Morgan Conference: Management of GBA Group Pharma is attending the JP Morgan Conference / Biotech Showcase in San Francisco, USA, on 12th -15th January 2020.

Further Information: 

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)